Загрузка...
An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial
BACKGROUND: The number of injections in the dose escalation of subcutaneous immunotherapy (SCIT) is small for some currently used hypoallergenic allergoids, but can still be inconvenient to patients and can impair compliance. The aim of this trial was to compare safety and tolerability of an acceler...
Сохранить в:
| Опубликовано в: : | Clin Transl Allergy |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4736162/ https://ncbi.nlm.nih.gov/pubmed/26839682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13601-016-0093-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|